These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 15974572)

  • 21. Structure-guided development of specific pyruvate dehydrogenase kinase inhibitors targeting the ATP-binding pocket.
    Tso SC; Qi X; Gui WJ; Wu CY; Chuang JL; Wernstedt-Asterholm I; Morlock LK; Owens KR; Scherer PE; Williams NS; Tambar UK; Wynn RM; Chuang DT
    J Biol Chem; 2014 Feb; 289(7):4432-43. PubMed ID: 24356970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HSP90: chaperone-me-not.
    Patki JM; Pawar SS
    Pathol Oncol Res; 2013 Oct; 19(4):631-40. PubMed ID: 23900891
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of gastric tumor growth by a novel Hsp90 inhibitor.
    Lu C; Liu D; Jin J; Deokar H; Zhang Y; Buolamwini JK; Yu X; Yan C; Chen X
    Biochem Pharmacol; 2013 May; 85(9):1246-56. PubMed ID: 23415900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Co-crystalization and in vitro biological characterization of 5-aryl-4-(5-substituted-2-4-dihydroxyphenyl)-1,2,3-thiadiazole Hsp90 inhibitors.
    Sharp SY; Roe SM; Kazlauskas E; Cikotienė I; Workman P; Matulis D; Prodromou C
    PLoS One; 2012; 7(9):e44642. PubMed ID: 22984537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thermodynamics of aryl-dihydroxyphenyl-thiadiazole binding to human Hsp90.
    Kazlauskas E; Petrikaitė V; Michailovienė V; Revuckienė J; Matulienė J; Grinius L; Matulis D
    PLoS One; 2012; 7(5):e36899. PubMed ID: 22655030
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hot spot analysis for driving the development of hits into leads in fragment-based drug discovery.
    Hall DR; Ngan CH; Zerbe BS; Kozakov D; Vajda S
    J Chem Inf Model; 2012 Jan; 52(1):199-209. PubMed ID: 22145575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hit clustering can improve virtual fragment screening: CDK2 and PARP1 case studies.
    Zeifman AA; Stroylov VS; Novikov FN; Stroganov OV; Zakharenko AL; Khodyreva SN; Lavrik OI; Chilov GG
    J Mol Model; 2012 Jun; 18(6):2553-66. PubMed ID: 22069029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis, and evaluation of small molecule Hsp90 probes.
    Taldone T; Zatorska D; Patel PD; Zong H; Rodina A; Ahn JH; Moulick K; Guzman ML; Chiosis G
    Bioorg Med Chem; 2011 Apr; 19(8):2603-14. PubMed ID: 21459002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A combined molecular modeling study on a series of pyrazole/isoxazole based human Hsp90α inhibitors.
    Yang Y; Liu H; Du J; Qin J; Yao X
    J Mol Model; 2011 Dec; 17(12):3241-50. PubMed ID: 21369933
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enaminones as building blocks for the synthesis of substituted pyrazoles with antitumor and antimicrobial activities.
    Riyadh SM
    Molecules; 2011 Feb; 16(2):1834-53. PubMed ID: 21343888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma.
    Gaspar N; Sharp SY; Eccles SA; Gowan S; Popov S; Jones C; Pearson A; Vassal G; Workman P
    Mol Cancer Ther; 2010 May; 9(5):1219-33. PubMed ID: 20457619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of hepatic stellate cell proliferation by heat shock protein 90 inhibitors in vitro.
    Sun X; Zhang XD; Cheng G; Hu YH; Wang HY
    Mol Cell Biochem; 2009 Oct; 330(1-2):181-5. PubMed ID: 19412730
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Different poses for ligand and chaperone in inhibitor-bound Hsp90 and GRP94: implications for paralog-specific drug design.
    Immormino RM; Metzger LE; Reardon PN; Dollins DE; Blagg BS; Gewirth DT
    J Mol Biol; 2009 May; 388(5):1033-42. PubMed ID: 19361515
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery and development of heat shock protein 90 inhibitors.
    Taldone T; Sun W; Chiosis G
    Bioorg Med Chem; 2009 Mar; 17(6):2225-35. PubMed ID: 19017562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Divergent synthesis of a pochonin library targeting HSP90 and in vivo efficacy of an identified inhibitor.
    Barluenga S; Wang C; Fontaine JG; Aouadi K; Beebe K; Tsutsumi S; Neckers L; Winssinger N
    Angew Chem Int Ed Engl; 2008; 47(23):4432-5. PubMed ID: 18435518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heat shock protein 90: the cancer chaperone.
    Neckers L
    J Biosci; 2007 Apr; 32(3):517-30. PubMed ID: 17536171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Benchmarking sets for molecular docking.
    Huang N; Shoichet BK; Irwin JJ
    J Med Chem; 2006 Nov; 49(23):6789-801. PubMed ID: 17154509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein.
    Waza M; Adachi H; Katsuno M; Minamiyama M; Tanaka F; Doyu M; Sobue G
    J Mol Med (Berl); 2006 Aug; 84(8):635-46. PubMed ID: 16741751
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heat shock proteins as emerging therapeutic targets.
    Sõti C; Nagy E; Giricz Z; Vígh L; Csermely P; Ferdinandy P
    Br J Pharmacol; 2005 Nov; 146(6):769-80. PubMed ID: 16170327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design.
    Dymock BW; Barril X; Brough PA; Cansfield JE; Massey A; McDonald E; Hubbard RE; Surgenor A; Roughley SD; Webb P; Workman P; Wright L; Drysdale MJ
    J Med Chem; 2005 Jun; 48(13):4212-5. PubMed ID: 15974572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.